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Summary
Parkinson’s disease is a neurodegenerative
disorder that is caused by the loss of dopaminergic
neurons in the substantia nigra. Misfolding of α-
synuclein is thought to cause this selective cell
death. In our α-synuclein yeast overexpression
model, we previously demonstrated that α -
synuclein, is non-toxic to yeast, runs 8-10 kDa
higher on protein gels and aggregates minimally in
vivo.  Recently, a new familial mutant of a-synuclein
E46K was discovered. α-Synuclein is a diversely
post-translationally modified protein and we
hypothesized that one of these modifications may
underlie its aberrant size. Here, we show that E46K
is more toxic to yeast than other familial α -
synuclein mutants. α-Synuclein mutants lacking
key phosphorylation and nitrosylation sites are
surprisingly toxic as well, but do not account for α-
synuclein’s aberrant size.  Interestingly, all these
mutants localize to the periphery of yeast cells and
show variable levels of in vivo aggregation.
Introduction
Accumulation of misfolded proteins as insoluble
aggregates occurs in several neurodegenerative
diseases including Parkinson’s disease (PD) (Dawson,
2003). PD is the second most common and fatal
neurodegenerative disorder in the aging population.
Symptoms of PD include resting tremor, rigidity,
slowness of movement, gait disturbances, and postural
instability (Dawson, 2003).  These symptoms are
believed to be due to the loss of dopaminergic neurons
in the substantia nigra, which is accompanied by the
formation of insoluble inclusions known as Lewy bodies
(LBs). Lewy bodies contain the misfolded protein α-
synuclein (Sharon et al., 2003). It has been shown that
the formation of these α-synuclein aggregates
coincides with disease onset and the symptoms
observed  (Giasson et al., 2002). α-Synuclein was first
associated with PD when a missense mutation (A53T)
in the gene encoding this cytosolic protein was linked to
a rare, familial dominant form of PD (Polymeropoulos et
al., 1997). A second missense mutation (A30P) was
then found in another PD family (Kruger, et al., 1998).
Just recently, a new familial mutation, E46K was
discovered, however, it has yet to be characterized
(Zarranz, 2004).  Despite the rarity of these α-synuclein
mutations, which account for only 5% of the all cases
observed in PD, their recognition has opened up the
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field of PD research (Sharon et al., 2003) However,
sporadic PD accounts for 95% of all cases.  In sporadic
PD the misfolding of normal wild-type α-synuclein is a
spontaneous event.
α-Synuclein is a small 140 amino acid (sizing
to 14 kDa), natively unfolded, heat stable, soluble
protein. It is abundant in the brain and is estimated to
constitute approximately 1% of total brain proteins, and
is localized primarily near presynaptic terminals of
neurons (Clayton and George et al., 1998). Even
though α-synuclein is a heat stable protein and natively
unfolded, it can aggregate in cells to form
proteinaceous inclusions under pathological conditions
(Duda et al., 2000).  The A53T familial mutant of α-
synuclein appears to induce disease onset by
increasing fibril formation; in vitro studies have shown
that recombinant mutant A53T α -synuclein protein
fibrillizes faster than wild-type α-synuclein (Conway et
al., 2000; Giasson et al., 1999).  These and other α-
synuclein inclusions have been shown to contain high
molecular weight insoluble α-synuclein proteins that are
resistant to strong denaturing conditions; this suggests
that α-synuclein proteins within these inclusions are
covalently cross-linked (Tu et al., 1998; Norris et al.,
2003).  The biochemical factors that induce aberrant α-
synuclein aggregation and the precise molecular
alterations of α-synuclein that lead to the formation of
pathological inclusions remains poorly understood
(Paxinou et al., 2001).
Post-translational modifications of α -
synuclein may be responsible for the formation of the
proteinaceous inclusions seen in PD patients. Recent
studies support a role for oxidative and/or nitrative
stress in α-synuclein post-translational modifications.
Previous studies have shown that α-synuclein was
nitrated in pathological lesions such as LBs (Giasson et
al., 2000).  Furthermore, other studies have indicated
that nitrating agents such as peroxynitrite/CO2 or
myeloperoxidase/H2O2/nitrite can nitrate and oxidize α-
synuclein at tyrosine (Tyr) residues, resulting in the
formation of highly stable dityrosine oligomers (Souza
et al., 2000).  Cross-linking or the formation of covalent
bonds between amino acids on the same or different
molecules of α-synuclein was observed when human
recombinant α-synuclein was exposed to nitrating
agents aw well (Souza et al., 2002).The formation α-
synuclein filaments by nitrating agents, provides
evidence for a role for nitrating–agent induced
modifications in the stabilization of α -synuclein
inclusions (Souza et al., 2000).  Other studies have also
shown that oxidation by dopamine, inhibited the
conversion of protofibrils to fibrils, leading to the
accumulation of α-synuclein protofibrils (Conway et al.,
2001).  Additionally, it was investigated if nitration and
oxidization induced the aggregation of a-synuclein.
Human embryonic cells (HEK 293) transfected with
wild-type and mutant α-synuclein exposed to nitrating
and oxidizing agents had extensive formation of α-
synuclein intracellular aggregates (Paxinou et al.,
2001).   The role of oxidative and /or nitrative species
on the conversion of monomeric, soluble α-synuclein to
soluble oligomers and finally to insoluble α-synuclein
inclusions remains unclear (Norris et al., 2003).  It is
known that Tyr residues and serine residues in α -
synuclein are targets for nitration (Souza et al., 2000).
A recently published yeast model of α -
synuclein expression in yeast (Outerio and Lindquist,
2003) showed that α-synuclein localized to the plasma
membrane, formed intracellular inclusions, and
influenced vesicle trafficking in wild-type cells.  Our lab
has recently developed a Saccharomyces cerevisiae
(S. cerevisiae) model to study protein misfolding
associated with PD (Johnson 2003; Sharma 2004).  In
this model wild-type, and the two-disease-associated
forms of α-synuclein, A30P and A53T, and the artificial
double mutant (A30P/A53T) were expressed in yeast.
Multiple sizes for all four of α-synuclein were observed,
with a majority of proteins appearing to be ~10 kDa
higher in size than the predicted 14 kDa size (Johnson,
2003). This may be due to in vivo post-translational
modifications of α-synuclein (i.e. by addition of nitro,
oxy, or phosphoryl groups). Our yeast model showed
that wild-type (WT) and mutant forms of α-synuclein do
not cause toxicity to yeast cells. Furthermore, GFP-
tagged WT, A53T, and double mutant (A30P/A53T) α-
synuclein localize to the membrane of yeast cells, while
A30P protein remained diffused in the cytoplasm. WT,
A53T and A30P/A53T α -synuclein also showed
formation of foci in the cytoplasm.
In this study, we investigated the role of the
familial mutant E46K in α -synuclein aggregation,
toxicity, and expression.  Additionally, we investigated
the role of Tyr residues at amino positions 39, 125 and
the serine residue at position 129 in α-synuclein post-
translational modification, aggregation formation,
toxicity, and localization.
Results
Expression of S129A, Y39F, and Y125F mutants and
the Familial Mutant E46K
Western analysis was conducted with lysates made for
cells expressing the four mutant (S129A, Y39F, Y125F,
and E46K) forms of α-synuclein in order to compare the
expression of α-synuclein.  Wild-type and mutant α-
synucleins were subcloned into yeast pYES2.1
expression vector under the control of a galactose-
inducible promoter GAL1.  Growing cells in the
presence of galactose induced optimal expression by
24 hours. α-Synuclein expression of these mutants has
not been previously shown.  Lysates were run on
denaturing gels; all forms of GFP-tagged α-synuclein
migrated at ~62 kDa. This expression has been
previously described among other mutant forms of α-
synuclein (Sharma, 2004).  Anti-V5 antibody was used
for protein detection (Figure 1).  α-Synuclein was
visualized by staining with Coomassie Blue. The
Coomassie stain showed that equal amounts of protein
were loaded into each lane (data not shown).  All forms
of GFP-tagged α-synuclein showed similar levels of α-
synuclein expression and gels showed a lack of SDS
insoluble aggregates of the mutant forms α-synuclein
because proteins were not observed at high molecular
weights.  However, it was expected that E46K mutant
α-synuclein would display protein bands at higher
molecular weight because of the possible presence of
aggregated α-synuclein. Additionally, it was expected
that S129A, Y39F, and Y125F mutant α-synuclein
would migrated at a lower molecular weight of ~52 kDa
because they lack the sites necessary for post-
translational modification.
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Figure 1: ? -Synuclein Expression In Newly Created Mutants.. 
(A) GFP alone migrated at ~34kDa, and the major band for the wild -type ? -synuclein-GFP(CT) fusion protein was 
observed at ~62kDa.  When expressed the fusion protein in the newly created mutants a similar expression pattern was 
observed.  A  prominent band at ~62kDa was observed for the various mutant ? -synuclein-GFP(CT) fusion proteins. The 
Anti -V5 antibody was used for protein detection.  MW = Molecular Weig ht Marker.   Coomassie control staining of all 
proteins in lysates showed that an equal amount of proteins were loaded in each lane.
Figure 1. α-Synuclein Expression In Newly Created Mutants
GFP alone migrated at ~34kDa, and the major band for the
wild-type α-synuclein-GFP(CT) fusion protein was observed at
~62kDa.  When expressed the fusion protein in the newly
created mutants a similar expression pattern was observed.  A
prominent band at ~62kDa was observed for the various mutant
α-synuclein-GFP(CT) fusion proteins. The Anti-V5 antibody was
used for protein detection.  MW = Molecular Weight Marker.
S129A, Y39F, and Y125F is Toxic to Yeast
To assess if α-synuclein expression was toxic to yeast
cells, optical density and spotting analyses were
performed. Optical density readings were taken during
logarithmic growth phase. α-Synuclein toxicity of these
mutants has not been previously shown, but
surprisingly cells expressing S129A, Y39F, and Y125F
mutant forms of α-synuclein showed major growth
deficiencies compared to cells expressing wild-type α-
synuclein (Figure 2A).  It was expecte  that th se
mutants would show a reduction in α-synuclein toxicity
because these mutants lack key sites for post-
translational modification.  For a more sensitive toxicity
assay, we spotted five-fold, serially diluted yeast cells
onto plates containing inducing (galactose) and non-
inducing (glucose) media (Figure 2C).  Cells expressing
wild-type α-synuclein grew similarly to cells carrying the
parent vector.  There was an observed mild growth
defect for cells expressing Y39F, Y125F, and S129A
mutant α-synuclein (Figure 2C).  These results are
consistent with the toxicity observed in the optical
density assay, however, a smaller lag growth was
observed.  The controlled cells expressing GFP showed
no lag in growth compared to the cells expressing
parent plasmid alone.  The glucose plates served as
controls and showed that cell density within each
dilution was equal in that each column showed similar
cell growth (Figure 2C).
S129A, Y39F, and Y125F Localize Near Yeast
Plasma Membranes
In order to investigate the localization of α-synuclein in
live yeast cells, we tagged wild-type and the mutant
forms of α-synuclein with GFP.  GFP served as a visual
marker for the protein α-synuclein.   GFP was tagged to
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Figure 2:  ? -Synuclein Inhibits Growth Selectively. OD600 readings were taken at several time points for yeast cells 
induced for ? -synuclein expression.  When compared to cells containing just th e parent plasmid (pYES2), ? -synuclein 
expression did not have a drastic effect on growth for A30P. A53 T and A53T/A30P mutants. The E46K mutant showed a 
large lag growth compared to wild -type ? -synuclein and other mutant ? -synucleins. (B) All mutants showed a lag in 
growth rate when compared to the wild -type ? -synuclein expressing cells . (C) Growth was also analyzed by spotting 
five- fold-serially diluted yeast cells on plates containing non -inducing (glucose) or inducing (galactose) medium. All yeast 
cells grew to the same extent on non -inducing plates. On inducing plates, cells expressing the Y39F, Y125F, and S129A 
mutant ? -synuclein  displayed modest growth defects, but not wild -type ? -synuclein or cells expressing parent plasmid 
alone. 
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Figure 2.  α-Synuclein Inhibits Growth Selectively
OD600 readings were taken at several time points for yeast cells induced for α-synuclein expression.  When compared to cells containing
just the parent plasmid (pYES2), α-synuclein expression did not have a drastic effect on growth for A30P, A53T and A53T/A30P mutants.
The E46K mutant showed a large lag growth compared to wild-type a-synuclein and other mutant α-synucleins. (B) All mutants showed a
lag in growth rate when compared to the wild-type a-synuclein expressing cells. (C)  Growth was also analyzed by spotting five-fold-serially
diluted yeast cells on plates containing non-inducing (glucose) or inducing (galactose) medium. All yeast cells grew to the same extent on
non-inducing plates. On inducing plates, cells expressing the Y39F, Y125F, and S129A mutant a-synuclein displayed modest growth
defects, but not wild-type a-synuclein or cells expressing parent plasmi  alone.
the C-terminus of the α-synuclein gene because the α-
synuclein protein as more stable and it maintained the
folding and activity of α-synuclein to a better extent.
Due to the t xicity of S129A, Y39F, and Y125F in yeast
cells, we conducted live cell fluorescence microscopy to
determine if α-synuclein localized differently in the
dying yeast cells compared to the parent strain.  α-
Synuclein was expressed for 24 hours in galactose
media. C-terminal GFP-tagged wild-type and Y39F,
Y125F, S129A, mutant α-synuclein localized near the
cell membranes of yeast (Figu  3A). When the GFP
control protein was expressed it remained primarily
distributed throughout the cells cytoplasm as expected
(Rines et al., 2002).  These findings are consistent with
previous α-synuclein localization studies observed in
our lab  (Sharma, 2004).    However, it  was unexpected
A. 
S129A-GFPY125F-GFPY39F-GFPGFP 
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Figure 3. Fluorescence Patterns in Yeast
(A) With GFP fluorescence, (top panel), Y39F. Y125F, and S129A mutants displayed bright halos, indicating α-synuclein’s localization near
yeast plasma membranes. Control cells (with vectors containing the GFP gene alone) showed diffuse fluorescent staining, and GFP was
distributed throughout the cell.  (B) Wild-type, E46K, A53T, and double mutant α-synuclein (tagged with CT-GFP) displayed bright halos. A
small number of cells expressing the mutant forms A53T and E46K displayed foci that could be indicative of α-synuclein’s aggregation. The
A30P mutant α-synuclein, however, remained distributed within the cytosol.
that the S129A, Y39F, and Y125F mutant showed
toxicity when expressed in yeast cells but there was no
observed change in its localization.
E46K is Toxic to Yeast
We further questioned whether the expression of E46K
mutant α-synuclein affected growth of yeast cells.
Previous studies have shown that α-synuclein is toxic
to neurons (Masliah, E., et al., 2000).  Again, optical
density readings and spotting assays were performed
during logarithmic growth phase. Minor differences
were observed between the growth rates of the control
parent vector  and GFP cells and cells expressing wild-
type α-synuclein and A30P, A53T, and A53T/A30P
mutant α -synuclein (Figure 2B).  However, cells
expressing E46K mutant α-synuclein showed a major
lag in growth compared to cells carrying the parent
vector or those expressing wild-type α -synuclein.
Spotting assays showed different results compared to
the optical density assays.  Cells expressing wild-type
and the various familial mutant forms of α-synuclein
grew to the same extent as cells with the parent vector
and control GFP protein. The glucose plates served as
controls and showed that cell density within each
dilution was equal in that each column showed similar
cell growth (Figure 2C).
E46K Localizes Near Plasma Membrane and Forms
Cytoplasmic Foci
C-terminal GFP-tagged E46K mutant α-synuclein
showed similar α-synuclein localization as S129A,
Y39F, and Y125F mutants.  Again, α-synuclein was
expressed in the parent strain and cells containing the
E46K mutant for 24 hours in galactose media.  E46K,
A53T, and A30P/A53T α-synuclein localized near the
periphery of the cell (Figure 3B).  Additionally, a small
population of cells expressing E46K and A53T mutant
α-synuclein formed foci in the cytoplasm (Figure 3B).
The A30P mutant did not localize to the periphery and it
remained distributed throughout the cytoplasm (Figure
3B).  The A30P/A53T double mutant showed an
intermediary phenotype (Figure 3B).  The protein
mainly remained distributed throughout the cytoplasm
and to a lesser extent it localized to the cell membrane.
Furthermore, the GFP control was primarily distributed
throughout the cytoplasm.
Discussion
The main goal of Parkinson’s disease research is to
find an effective way to reverse or avoid the protein
aggregation of α-synuclein and the neuronal death
associated with this disease.  Many animal models
have been developed to understand the pathology of
Parkinson’s disease; models have focused on
evaluating the potential toxicity of α-synuclein and the
effects it has on the advancement of PD. However,
many of the pathological aspects of PD still remain
unclear.  S. cerevisiae has served as an excellent
model for studying many facets of Parkinson’s.
Through this model we have been able to examine the
protein folding and misfolding of α-synuclein.
α -Synuclein increased size is not due to
phosphorylation at Serine 129 and nitrosylation at
Tryosines 39 or 125
Previous Western analysis conducted in our lab has
shown that a-synuclein from yeast lysates migrates to ~
62 kDa in denaturing protein gels in contrast to the
predicted mass of 53 kDa (14 kDa for α-synuclein
protein, 34 kDa for GFP protein, and 5 kDa epitope
tags).  Thus, α-synuclein migrates ~8-10 kDa higher
than predicted.  In both human patients and E.coli
models, α-synuclein runs at its predicted size rarely
(Conway et al., 2000).  Our observed 62 kDa α -
synuclein band is consistent with these findings.  We
believed that α-synuclein migrated to a higher predicted
molecular weight due to post-translational modifications
located on Serine 129, Tyrosine 39 and 125.  The
serine 129 residue of α-synuclein has been linked to
phosphorylation modifications and tyrosine 39 and 125
has been linked to nitrosylation modifications.  Thus, in
this study we used site-directed mutagenesis to alter
these residues to examine if they contribute to specific
post-translational modifications in  α-synuclein.
However, the western analysis showed that there was
no change in the migration pattern of these altered α-
synucleins (S129A, Y39F, and Y125F).  These findings
suggest that α-synuclein’s increased size is not due to
phosphorylation at serine 129 and nitrosylation at
tyrosines 39 and 125.
Other studies have shown that α-synuclein
may run higher than expected due to a glycosylation
modification (Shimura et al., 2001).  Additionally, other
studies have shown that α-synuclein may run at a
higher molecular weight than predicted because of
lipidation (Sharon et al., 2001).  Finally, α-synuclein has
is misfolded in neurons.  When proteins become
misfolded they are ubiquitinated by a cascade of
ubiquitin enzymes in the ubiquitin proteasome pathway
(Ciechanover and Brundin, 2003).  Thus, α-synuclein
may be running higher due to ubiquitin post-
translational modifications at lysine residues.  We are
unsure why α-synuclein migrates to 62 kDa in our
study, but it may be due to one or more of these three
forms of post-translational modifications.
S129A, Y39F, and Y125F Showed Unexpected Toxic
properties
The optical density and spotting results indicate that
when S129A, Y39F, and Y125F α -synuclein is
expressed in yeast cells; they are less viable than cells
expressing wild-type α-synuclein.  These results were
unexpected because post-translational modifications of
α-synuclein, such as nitrosylation and phosphorylation
may be responsible for the formation of the
proteinaceous inclusions seen in PD patients (Giasson
et al., 2000). It has been shown that the formation of
these α-synuclein aggregates coincides with disease
onset and the symptoms observed (Giasson et al.,
2002).  Thus, by altering the sites in α-synuclein that
are responsible for nitrosylation and phosphorylation we
would see less toxicity, however, the exact opposite
was observed.  In fact, these results suggest that these
post-translational modifications are beneficial not
detrimental to cells expressing α-synuclein.  When cells
are expressing α-synuclein with unaltered 39, 125, 129
residues no toxicity is observed in both spotting and
optical density assays.
In Vivo Membrane Association of S129A, Y39F, and
Y125F α-Synuclein
S129A, Y39F, and Y125F α-synuclein has extensive
peripheral localization in live yeast cells.  This is
consistent with the live yeast cell microscopy
experiments conducted by Sharma, 2004.  However,
initially it was expected that α-synuclein would be
distributed throughout the yeast’s cytosol, with foci to
indicate aggregation formation of the protein. α -
Synuclein’s association to yeast plasma membranes
agrees with the research findings pertaining to α-
synuclein’s interaction with lipids.   In α-synuclein’s
amino acid sequence there is a 11-residue repeat,
which is common among apolopoproteins; this repeat
sequence is believed to be responsible for its ability to
bind synthetic phospholipid vesicles (Davidson et al.,
1998). α-Synuclein has motifs that resemble those of
fatty-acid binding proteins, and α-synuclein binds to
fatty-acids in vitro (Sharon et al., 2001). Current
research has implicated that α-synuclein interacts with
dopamine transporters on the neuronal membrane and
it regulates the amount of dopamine that enters the cell
(Wersinger et al., 2003). This finding suggests a
possible functional role of α-synuclein.  In our research
α -synuclein’s association to the yeast plasma
membrane demonstrates its ability to bind to
phospholipids (Sharma, 2004). The cytoplasm of yeast
cells is much smaller that that of neurons, thus α-
synuclein may have an easier ability to bind
phospholipids in yeast membranes (Sharma, 2004).
E46K does not form SDS-insoluble aggregates
Western analysis showed that the familial mutant E46K
migrates at ~62 kDa.  Previous Western analysis
conducted in our lab has shown that α-synuclein from
yeast lysates expressing wild-type α-synuclein and the
other familial mutants A53T and A30P migrates to ~62
kDa in denaturing protein gels (Sharma, 2004).
However, it was expected that E46K α -synuclein
expression would show multiple high running bands
that correspond to dimers and aggregates because a
case study in 2003 stated that E46K mutant form of α-
synuclein is more prone to aggregation compared to the
other familial mutants (Zarranz, et al, 2003). Hence in
our studies, E46K α-synuclein may not be aggregating
to dimers and higher order structures to significant
amounts in yeast cells, or aggregates do form but are
separated during denaturation steps before loading
proteins on gels for electrophoresis analysis.
E46K Toxicity May Be Due To Increased Misfolding
In PD, one hypothesis for the death of substantia nigra
neurons is that misfolded/aggregated α-synuclein
creates toxic conditions.  In mice and fruit fly models
overexpression of α-synuclein results in cell death
(Masliah et al. 2000; Feany and Bender, 2000). Thus it
was expected that α-synuclein expression of E46K
would decrease cell viability to some extent.  The
optical density results show that cells expressing
mutant E46K α-synuclein had a large lag in growth
compared to cells expressing wild-type and A53T,
A30P, and A53T/A30P mutant forms of α-synuclein.
Previous studies conducted in our lab have shown that
the mutant forms A53T, A30P, and A53T/A30P only
exhibit a slight lag in growth in both optical density and
spotting assays (Sharma, 2004).  However, spotting
assays show that the E46K mutant shows no difference
in growth compared to cells carrying parent vector or
other forms of α-synuclein.  Thus, toxicity assays
should be repeated again to make any significant
conclusions about E46K toxicity.
GFP microscopy results show that at 24
hours of expression, when toxicity is occurring, E46K α-
synuclein has extensive peripheral localization in live
yeast cells, again suggesting α-synuclein’s affinity for
lipids. In addition, our GFP microscopy studies show
that the E46K mutant is more prone to aggregation
compared to the A53T mutant. This observed increase
in aggregation of E46K α-synuclein may relate to the
increase in toxicity observed in yeast cells expressing
this protein, because it is proposed that neurons die
due to the toxic conditions α-synuclein creates when it
is misfolded (see proposed Model in Figure 4).
Furthermore, we found that the A30P mutant does
localize to plasma membranes, thus this mutation may
reduce α-synuclein’s affinity for lipids. Some studies
show that the A30P familial mutation greatly reduces α-
synuclein’s ability to bind to lipids (Jensen et al., 1998;
Cole et al., 2002). However, other studies find that the
A30P mutations have little effect on lipid binding (Perrin
et al., 2000).  Our studies suggest that this mutation
causes  α-synuclein  to  lose lipid affinity, and  this  may
Figure 4.  Hypothetical Model Characterizing α-Synuclein’s Misfolding and Aggregation In Vivo
Live cell microscopy displayed different fluorescence patterns for yeast cells expressing wild-type and mutant α-synuclein tagged with GFP.
Abnormal formation of α-synuclein aggregates are highlighted by distinct fluorescent foci.  Mutant E46K α-synuclein displayed foci
formation that is indicative to aggregation.  Whereas wild-type α-synuclein localized to the plasma membrane of cells.   It was predicted
more foci would be seen in E46K-mutant cells as compared to their wild-type expressing cells.   This increase in foci formation for E46K
expressing cells may account for its observed toxicity.  It has been described that misfolded or aggregated α-synuclein may be toxic to
neurons in the substantia nigra of Parkinson’s disease patients.
prevent it from proceeding with its normal function
(Sharma, 2004). These results agree with in vitro
studies showing that α -synuclein aggregation is
accelerated by the A53T mutation (Conway et al., 1998;
Narhi et al., 1999).
The first yeast model published in 2003,
describes similar results to our GFP fluorescence
studies (Outerio and Lindquist, 2003). In this yeast
model, the wild-type and A53T mutant α-synuclein
forms showed peripheral localization.  The A30P
mutant form did not localize to the periphery and lead to
lipid accumulation.  However, they reported that wild-
type α-synuclein formed inclusions similar to those
seen in the A53T yeast model.  These results differ
from our lab’s findings in that we do not see inclusion
structures in our wild-type yeast model.
Conclusion
Our studies have enhanced our understanding of the
misfolding, aggregation, and post-translational
modifications of α-synuclein.  Western and GFP studies
imply that α-synuclein may not be nitrosylated or
phosphorylated.  Identification of other key post-
translational modifications may elucidate α-synuclein
misfolding in PD.  Additionally, evaluation of the newly
discovered E46K mutant recapitulates many properties
seen in α-synuclein behavior in PD patients including
increase toxicity with mutant α-synuclein.  Further
examination of this major toxicity observed in cells
expressing S129A, Y39F, Y125F, and E46K mutants
may aid in the discovery of factors that can inhibit or
correct α-synuclein misfolding.
Experimental Procedures
Preparation of Familial Mutant E46K and Tyr—Phe Mutant
α-Synuclein Proteins E46K, Y39F, Y125F, S129A, mutant α-
synucleins cDNAs were created using site-directed
mutagenesis (Invitrogen). 1.6 µL methylation buffer, 1.6 µL of
10X SAM buffer, 1 µL DNA methylase, and 10.8 µL of water
were added to 1 µL of purified plasmid DNA containing α-
synuclein.  The reactions were incubated at 37°C for one hour.
A PCR reaction was used to amplify vector DNA with a new
missense mutation.  Primers were designed to make the
particular mutations
     S129A:5’GCTTATGAAATGCCTGCTGAGGAAGGGTATCAA3’;
     Y125F: 5’CCTGACAATGAGGCTTTTGAAATGCCTTCTGAG3’
     Y39F:5’AAAGAGGGTGTTCTCTTTGTAGGCTCCAAAACC3’;
     E46K:5’ATGTAGGCTCCAAAACCAAGAAGGGAGTGGTGC3’.
These mutant cDNAs were expressed in Escherichia coli
DH5a-T1. α-Synuclein expression plasmids were transformed
as described (Burke, 2000) into URA-3-deficient S. cerevisiae
yeast strains. For selection, yeast cells were grown on
synthetic-complete media lacking uracil (SC-URA).  Presence
of α-synuclein constructs was confirmed by polymerase-chain
reaction.  The pYES2.1 vector, containing a galactose inducible
promoter (GAL1), allowed for regulated α-synuclein expression.
Table 1 lists all α-synuclein-GFP constructs in yeast expression
vectors that were investigated.
Table 1. List of α-synuclein-GFP constructs in Yeast
Expression Vectors
GFP Microscopy and Quantification
Yeast cells were viewed under the Zeiss Axiovert-100
fluorescent microscope and images were acquired under blue-
filter settings and deconvoluted using the Metamorph 4.0
imaging software.  Quantification was carried out by counting
Construct Vectors
WT α-Synuclein-GFP(CT) TOPO PYES 2.1
A30P α-Synuclein-GFP(CT)      “
A53T α-Synuclein-GFP(CT)      “
A30P/A53T α-Synuclein-GFP(CT)      “
E46K α-Synuclein-GFP(CT)      “
Y39F  α-Synuclein-GFP(CT)      “
Y125F  α-Synuclein-GFP(CT)      “
S129A α-Synuclein-GFP(CT)      “
GFP      “
Wild-type
α-Synuclein
Misfolded E46K
α-Synuclein
Toxicity
Increased Foci Formation
No Toxicity
α-Synuclein Folding
Live Cell
Microscopy
cells in several areas of the slide and calculating the ratio of
cells displaying certain patterns: general fluorescence
(cytoplasmic localization), bright halos (peripheral localization),
and foci (possible aggregation).
Western Analyses
Yeast cells (2.5x107 cells/ml) were washed in 50mM Tris (pH
7.5), 10mM NaN3 and solubilized in Electrophoresis Sample
Buffer (ESB; Burke, 2000) containing 2% SDS, 80mMTris (ph
6.8), 10% glycerol, 1.5% DTT, 1mg/ml bromophenol blue, and a
cocktail of protease inhibitors and solubilizing agents (1%
Triton-X 100, 1mM PMSF, 1mM benzamidine, 1mM sodium
orthovanadate, 0.7 µg/ml pepstatin A, 0.5 µg/ml leupeptin,
10µg/ml E64, 2µg/ml aprotinin, and 2µg/ml chymostatin).
Samples were run on pre-cast 10-20% Tris-Glycine SDS gels
(Invitrogen), using SeeBlue as the molecular standard
(Invitrogen).  Gels were transferred to PVDF membranes and
probed with the antibody: anti-V5 (Invitrogen).
Growth Analyses
For OD600 analysis, absorbance readings of yeast cells
expressing α-synuclein were taken at 600nm using the Hitachi
U-200 spectrophotometer.  For spotting, cells were grown to
mid-log phase in SC-URA raffinose (2%), normalized to equal
densities, serially diluted (five-fold), and spotted on SC-URA
glucose (2%) or galactose (2%) plates.  Photographs were
scanned after 2-3 days of growth.
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